{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:28:31Z","timestamp":1793212111149,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd000296.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2015,6,3]],"date-time":"2015-06-03T00:00:00Z","timestamp":1433289600000}}],"reference-count":78,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd000296.pub4","type":"journal-article","created":{"date-parts":[[2015,6,4]],"date-time":"2015-06-04T05:10:24Z","timestamp":1433394624000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Budesonide for induction of remission in Crohn's disease"],"prefix":"10.1002","volume":"2015","author":[{"given":"Ali","family":"Rezaie","sequence":"first","affiliation":[{"name":"Cedars-Sinai Medical Center; Department of Medicine; Los Angeles California USA 90048"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Ellen","family":"Kuenzig","sequence":"additional","affiliation":[{"name":"University of Calgary; Department of Medicine; Calgary AB Canada"},{"name":"University of Calgary; Department of Community Health Sciences; Calgary AB Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric I","family":"Benchimol","sequence":"additional","affiliation":[{"name":"The Children's Hospital of Eastern Ontario; CHEO Inflammatory Bowel Disease Centre, Division of Gastroenterology Hepatology & Nutrition; 401 Smyth Road Ottawa Ontario Canada K1H 8L1"},{"name":"University of Ottawa; Department of Pediatrics, School of Epidemiology, Public Health and Preventive Medicine; Ottawa Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Marie","family":"Griffiths","sequence":"additional","affiliation":[{"name":"The Hospital for Sick Children; Division of Gastroenterology, Hepatology & Nutrition; 555 University Ave. Toronto ON Canada M5G 1X8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony R","family":"Otley","sequence":"additional","affiliation":[{"name":"IWK Health Centre; Head, Division of Gastroenterology; 5850 University Avenue Halifax NS Canada B3K 6R8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A Hillary","family":"Steinhart","sequence":"additional","affiliation":[{"name":"Mount Sinai Hospital; Department of Medicine, Division of Gastroenterology; Room 445, 600 University Avenue Toronto ON Canada M5G 1X5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilaad G","family":"Kaplan","sequence":"additional","affiliation":[{"name":"University of Calgary; Department of Medicine; Calgary AB Canada"},{"name":"University of Calgary; Department of Community Health Sciences; Calgary AB Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia H","family":"Seow","sequence":"additional","affiliation":[{"name":"University of Calgary; Department of Medicine; Calgary AB Canada"},{"name":"University of Calgary; Department of Community Health Sciences; Calgary AB Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,6,3]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD000296.pub4-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S0016-5085(98)70254-9","article-title":"Budesonide versus prednisone in the treatment of active Crohn's disease","volume":"115","author":"Bar-Meir","year":"1998","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD000296.pub4-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/gut.41.2.209","article-title":"Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group","volume":"41","author":"Campieri","year":"1997","journal-title":"Gut"},{"issue":"5","key":"10.1002\/14651858.CD000296.pub4-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1046\/j.1365-2036.1998.00321.x","article-title":"Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn's disease","volume":"12","author":"D'Haens","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1002\/14651858.CD000296.pub4-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/00042737-200401000-00008","article-title":"Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial","volume":"16","author":"Escher","year":"2004","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"13","key":"10.1002\/14651858.CD000296.pub4-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM199409293311303","article-title":"Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group","volume":"331","author":"Greenberg","year":"1994","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1002\/14651858.CD000296.pub4-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/00054725-200008000-00004","article-title":"Quality of life rapidly improves with budesonide therapy for active Crohn's disease","volume":"6","author":"Irvine","year":"2000","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"10.1002\/14651858.CD000296.pub4-BIB0007|cit7","first-page":"905","article-title":"Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. German\/Austrian Budesonide Study Group","volume":"8","author":"Gross","year":"1996","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"10.1002\/14651858.CD000296.pub4-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/00005176-200302000-00017","article-title":"A comparison of budesonide and prednisone for the treatment of active pediatric Crohn disease","volume":"36","author":"Levine","year":"2003","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"13","key":"10.1002\/14651858.CD000296.pub4-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJM199409293311304","article-title":"A comparison of budesonide with prednisolone for active Crohn's disease","volume":"331","author":"Rutgeerts","year":"1994","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1002\/14651858.CD000296.pub4-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.crohns.2012.06.006","article-title":"Efficacy and tolerability of oral budesonide in Japanese patients with active Crohn's disease: a multicentre, double-blind, randomized, parallel-group Phase II study","volume":"7","author":"Suzuki","year":"Apr 2013","journal-title":"J Crohns Colitis"},{"issue":"6","key":"10.1002\/14651858.CD000296.pub4-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1056\/NEJM199808063390603","article-title":"A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group","volume":"339","author":"Thomsen","year":"1998","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1002\/14651858.CD000296.pub4-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1572-0241.2002.05544.x","article-title":"Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life","volume":"97","author":"Thomsen","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"10.1002\/14651858.CD000296.pub4-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1111\/j.1572-0241.2002.05835.x","article-title":"Budesonide CIR capsules one or twice daily in active Crohn's disease. A randomized placebo controlled study in the USA","volume":"97","author":"Tremaine","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1002\/14651858.CD000296.pub4-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1053\/j.gastro.2010.11.004","article-title":"Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease","volume":"140","author":"Tromm","year":"Feb 2011","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD000296.pub4-BIB0015|cit15","first-page":"PI29","article-title":"Beclomethasone dipropionate for the treatment of mild-to-moderate Crohn's disease: an open-label, budesonide-controlled, randomized study","volume":"12","author":"Tursi","year":"2006","journal-title":"Med Sci Monit"},{"issue":"2","key":"10.1002\/14651858.CD000296.pub4-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-2036.1995.tb00367.x","article-title":"Budesonide and prednisolone suppress peripheral blood natural killer cells in Crohn's disease","volume":"9","author":"Ierssel","year":"1995","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1002\/14651858.CD000296.pub4-BIB0017|cit17","first-page":"21","article-title":"Comparison of budesonide with mesalazine in Crohn's disease. [Dutch]","volume":"33","author":"Anonymous","year":"1999","journal-title":"Geneesmiddelenbulletin"},{"issue":"14","key":"10.1002\/14651858.CD000296.pub4-BIB0018|cit18","first-page":"445","article-title":"Treatment of active and postactive ileal and colonic Crohn's disease with oral pH-modified-release budesonide. German Budesonide Study Group","volume":"44","author":"Caesar","year":"1997","journal-title":"Hepatogastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD000296.pub4-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1136\/gut.48.2.186","article-title":"Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease","volume":"48","author":"Cortot","year":"2001","journal-title":"Gut"},{"issue":"9","key":"10.1002\/14651858.CD000296.pub4-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.crohns.2014.01.021","article-title":"Once versus three times daily dosing of oral budesonide for active Crohn's disease:A double-blind, double-dummy,randomised trial","volume":"8","author":"Dignass","year":"2014","journal-title":"Journal of Crohn's and Colitis"},{"issue":"3","key":"10.1002\/14651858.CD000296.pub4-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1080\/00365520310000645a","article-title":"Oral budesonide significantly improves water absorption in patients with ileostomy for Crohn disease","volume":"38","author":"Ecker","year":"2003","journal-title":"Scand J Gastroenterol"},{"issue":"3","key":"10.1002\/14651858.CD000296.pub4-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/00042737-199903000-00011","article-title":"Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: a multicentre randomized placebo-controlled trial. German Budesonide Study Group","volume":"11","author":"Ewe","year":"1999","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"10.1002\/14651858.CD000296.pub4-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1365-2036.1998.00285.x","article-title":"Oral budesonide as maintenance therapy in Crohn's disease--results of a 12-month study. Global Budesonide Study Group","volume":"12","author":"Ferguson","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1002\/14651858.CD000296.pub4-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1046\/j.1440-1681.2000.03238.x","article-title":"Treatment of joint pain in Crohn's patients with budesonide controlled ileal release","volume":"27","author":"Florin","year":"2000","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"12","key":"10.1002\/14651858.CD000296.pub4-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1097\/00042737-200112000-00006","article-title":"Association of HLA-DR genotypes and IL-1ra gene polymorphism with treatment failure of budesonide and disease patterns in Crohn's disease","volume":"13","author":"Gelbmann","year":"2001","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"9","key":"10.1002\/14651858.CD000296.pub4-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1046\/j.1365-2036.2001.01055.x","article-title":"Maintenance of Crohn's disease over 12 months: fixed versus flexible dosing regimen using budesonide controlled ileal release capsules","volume":"15","author":"Green","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1002\/14651858.CD000296.pub4-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1053\/gast.1996.v110.pm8536887","article-title":"Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group","volume":"110","author":"Greenberg","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD000296.pub4-BIB0028|cit28","unstructured":"Gross V Caesar I Andus T Vogelsang H Adler G Malchow H Replacement of systemic steroids by oral budesonide in patients with post-active or chronic Crohn's ileocolitis - a dose-finding study Gastroenterology 1997 A987"},{"key":"10.1002\/14651858.CD000296.pub4-BIB0029|cit29","unstructured":"Gross V Caesar I Andus T Vogelsang H Adler G Malchow H Dose-finding study with oral budesonide in patients with active Crohn's ileocolitis Gastroenterology 1997 A986"},{"issue":"4","key":"10.1002\/14651858.CD000296.pub4-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1136\/gut.42.4.493","article-title":"Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. The Budesonide Study Group","volume":"42","author":"Gross","year":"1998","journal-title":"Gut"},{"issue":"4","key":"10.1002\/14651858.CD000296.pub4-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2036.2005.02338.x","article-title":"Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial","volume":"21","author":"Hanauer","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1002\/14651858.CD000296.pub4-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0016-5085(99)70125-3","article-title":"Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group","volume":"116","author":"Hellers","year":"1999","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD000296.pub4-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00384-003-0529-5","article-title":"Analysis of the therapeutic efficacy of different doses of budesonide in patients with active Crohn's ileocolitis depending on disease activity and localization","volume":"19","author":"Herfarth","year":"2004","journal-title":"Int J Colorectal Dis"},{"issue":"1","key":"10.1002\/14651858.CD000296.pub4-BIB0034|cit34","first-page":"81","article-title":"Effects of budesonide therapy on quality of life in active Crohn's disease","volume":"18","author":"Irvine","year":"1996","journal-title":"Research & Clinical Forums"},{"issue":"1","key":"10.1002\/14651858.CD000296.pub4-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00005176-200107000-00013","article-title":"Controlled ileal release budesonide in pediatric Crohn disease: efficacy and effect on growth","volume":"33","author":"Kundhal","year":"2001","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"1","key":"10.1002\/14651858.CD000296.pub4-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1067\/mpd.2002.119992","article-title":"Evaluation of oral budesonide for treatment of mild and moderate exacerbations of Crohn's disease in children","volume":"140","author":"Levine","year":"2002","journal-title":"J Pediatr"},{"issue":"7","key":"10.1002\/14651858.CD000296.pub4-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/ibd.20881","article-title":"Comparison of two dosing methods for induction of response and remission with oral budesonide in active pediatric Crohn's disease: a randomized placebo-controlled trial","volume":"15","author":"Levine","year":"Jul 2009","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"10.1002\/14651858.CD000296.pub4-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1365-2036.1993.tb00141.x","article-title":"Oral budesonide in active Crohn's disease","volume":"7","author":"Lofberg","year":"1993","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1002\/14651858.CD000296.pub4-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/gut.39.1.82","article-title":"Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study","volume":"39","author":"Lofberg","year":"1996","journal-title":"Gut"},{"issue":"5","key":"10.1002\/14651858.CD000296.pub4-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0016-5085(99)70034-X","article-title":"A comparison of budesonide and mesalamine for active Crohn's disease","volume":"116","author":"Lowry","year":"1999","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD000296.pub4-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1053\/cgh.2003.50015","article-title":"Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease","volume":"1","author":"Mantzaris","year":"2003","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1002\/14651858.CD000296.pub4-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/ibd.20777","article-title":"Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease","volume":"15","author":"Mantzaris","year":"2009","journal-title":"Inflamm Bowel Dis."},{"issue":"5","key":"10.1002\/14651858.CD000296.pub4-BIB0043|cit43","first-page":"251","article-title":"Budesonide in glucocorticoid dependent chronic active Crohn's disease; a pilot study","volume":"33","author":"Novacek","year":"1995","journal-title":"Z Gastroenterol"},{"issue":"6","key":"10.1002\/14651858.CD000296.pub4-BIB0044|cit44","first-page":"968","article-title":"Treatment of active Crohn's disease with an oral slow-release budesonide formulation","volume":"88","author":"Roth","year":"1993","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"10.1002\/14651858.CD000296.pub4-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1111\/j.1572-0241.2005.41992.x","article-title":"Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials","volume":"100","author":"Sandborn","year":"2005","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1002\/14651858.CD000296.pub4-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1542-3565(04)00662-7","article-title":"Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease","volume":"3","author":"Schoon","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1002\/14651858.CD000296.pub4-BIB0047|cit47","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002913","article-title":"Budesonide for maintenance of remission in Crohn's disease","author":"Simms","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD000296.pub4-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1053\/gast.2002.34225","article-title":"Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial","volume":"123","author":"Steinhart","year":"2002","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1002\/14651858.CD000296.pub4-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1111\/j.1572-0241.1998.536_e.x","article-title":"Influence of topically and systemically active steroids on circulating leukocytes in Crohn's disease","volume":"93","author":"Tillinger","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"10.1002\/14651858.CD000296.pub4-BIB0050|cit50","unstructured":"Safety Study of Entocort for Children With Crohn's Disease Ongoing study November 2011"},{"issue":"3","key":"10.1002\/14651858.CD000296.pub4-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.iac.2005.05.003","article-title":"Molecular mechanisms and cellular effects of glucocorticosteroids","volume":"25","author":"Barnes","year":"2005","journal-title":"Immunol Allergy Clin North Am"},{"issue":"9573","key":"10.1002\/14651858.CD000296.pub4-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0140-6736(07)60751-X","article-title":"Inflammatory bowel disease: clinical aspects and established and evolving therapies","volume":"369","author":"Baumgart","year":"2007","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD000296.pub4-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","article-title":"Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study","volume":"70","author":"Best","year":"1976","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD000296.pub4-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"2","key":"10.1002\/14651858.CD000296.pub4-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.addr.2004.08.009","article-title":"Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide","volume":"57","author":"Fedorak","year":"2005","journal-title":"Adv Drug Deliv Rev"},{"issue":"7","key":"10.1002\/14651858.CD000296.pub4-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0895-4356(92)90054-Q","article-title":"Variance imputation for overviews of clinical trials with continuous response","volume":"45","author":"Follmann","year":"1992","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"10.1002\/14651858.CD000296.pub4-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/ajg.2011.70","article-title":"Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"American Jouranl of Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD000296.pub4-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"323-33; quiz 59","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"issue":"8167","key":"10.1002\/14651858.CD000296.pub4-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A simple index of Crohn's-disease activity","volume":"1","author":"Harvey","year":"1980","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD000296.pub4-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"344-54. * Autho","DOI":"10.1053\/j.gastro.2014.10.011","article-title":"Comparative Effectiveness of Immunosuppressants and Biologics for Inducing and Maintaining Remission in Crohn's Disease: A Network Meta-analysis","volume":"148","author":"Hazlewood","year":"Feb 2015","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD000296.pub4-BIB0061|cit61","article-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0.","author":"Higgins","year":"March 2011","journal-title":"The Cochrane Collaboration"},{"issue":"4","key":"10.1002\/14651858.CD000296.pub4-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/00005176-199105000-00005","article-title":"Development and validation of a pediatric Crohn's disease activity index","volume":"12","author":"Hyams","year":"1991","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"8","key":"10.1002\/14651858.CD000296.pub4-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1046\/j.1365-2036.2002.01289.x","article-title":"The effectiveness of budesonide therapy for Crohn's disease","volume":"16","author":"Kane","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1002\/14651858.CD000296.pub4-BIB0064|cit64","first-page":"795","article-title":"Setting a high threshold for noninferiority: mesalamine and budesonide in Crohn's disease.","volume":"18","author":"Levesque","year":"2011","journal-title":"Inflammatory bowel diseases"},{"key":"10.1002\/14651858.CD000296.pub4-BIB0065|cit65","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008870","article-title":"Aminosalicylates for induction of remission or response in Crohn's disease.","volume":"(12):CD008870.","author":"Lim","year":"2010","journal-title":"Cochrane Database Syst Rev."},{"issue":"2","key":"10.1002\/14651858.CD000296.pub4-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0016-5085(84)90409-8","article-title":"European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment","volume":"86","author":"Malchow","year":"1984","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD000296.pub4-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0025-7753(01)71716-2","article-title":"Budesonide in inflammatory bowel disease: a meta-analysis","volume":"116","author":"Nos","year":"2001","journal-title":"Med Clin (Barc)"},{"issue":"4","key":"10.1002\/14651858.CD000296.pub4-BIB0068|cit68","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000296.pub2","article-title":"Budesonide for induction of remission in Crohn's disease","author":"Otley","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD000296.pub4-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1046\/j.1365-2036.2000.00867.x","article-title":"Budesonide in the treatment of Crohn's disease: a meta-analysis","volume":"14","author":"Papi","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1002\/14651858.CD000296.pub4-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":"Certolizumab pegol for the treatment of Crohn's disease","volume":"357","author":"Sandborn","year":"2007","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1002\/14651858.CD000296.pub4-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab\u00a0as\u00a0induction\u00a0and\u00a0maintenance\u00a0therapy\u00a0for\u00a0Crohn's disease.","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1002\/14651858.CD000296.pub4-BIB0072|cit72","first-page":"CD000296","article-title":"Budesonide for induction of remission in Crohn's disease.","volume":"16","author":"Seow","year":"2008","journal-title":"Cochrane Database Syst Rev."},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD000296.pub4-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/0016-5085(79)90386-X","article-title":"National Cooperative Crohn's Disease Study: adverse reactions to study drugs","volume":"77","author":"Singleton","year":"1979","journal-title":"Gastroenterology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD000296.pub4-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/0016-5085(79)90385-8","article-title":"National Cooperative Crohn's Disease Study: results of drug treatment","volume":"77","author":"Summers","year":"1979","journal-title":"Gastroenterology"},{"issue":"15","key":"10.1002\/14651858.CD000296.pub4-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1002\/14651858.CD000296.pub4-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1136\/bmj.2.4884.375","article-title":"Cortisone in ulcerative colitis; preliminary report on a therapeutic trial","volume":"2","author":"Truelove","year":"1954","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD000296.pub4-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1136\/gut.21.4.279","article-title":"An index of inflammatory activity in patients with Crohn's disease","volume":"21","author":"Hees","year":"1980","journal-title":"Gut"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD000296.pub4-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/0016-5085(79)90383-4","article-title":"National Cooperative Crohn's Disease Study: study design and conduct of the study","volume":"77","author":"Winship","year":"1979","journal-title":"Gastroenterology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD000296.pub4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T10:19:11Z","timestamp":1698574751000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD000296.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane IBD Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,6,3]]},"references-count":78,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2015,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd000296.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,3]]}}}